Article
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jun 2013
Hertz D L, Roy S, Motsinger-Reif A A, Drobish A, Clark L S, McLeod H L, Carey L A, Dees E C
Abstract excerpt
BACKGROUND: Paclitaxel-induced neuropathy is an adverse event that often leads to therapeutic disruption and patient discomfort. We attempted to replicate a previously reported association between increased neuropathy risk and CYP2C8*3 genotype. PATIENTS AND METHODS: Demographic, treatment, and toxicity data were collected for paclitaxel-treated breast cancer patients who were genotyped for the CYP2C8*3 K399R...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.